Claims
- 1. A method for treating dyslipidemia in a patient in need thereof, said method comprising administration to said patient of an effective amount of a glucagon-like peptide 1 (GLP-1) compound and an effective amount of an antidyslipidemic drug.
- 2. The method according to claim 1, wherein the GLP-1 compound is a stable derivative of a GLP-1 analog.
- 3. The method according to claim 1, wherein the GLP-1 compound is Arg34, Lys26(Nε(γ-Glu(Nα-hexadecanoyl)))-GLP-1 (7-37).
- 4. The method according to claim 1, wherein the GLP-1 compound is exendin-4 or an analog or derivative thereof.
- 5. The method according to claim 1, wherein said antidyslipidemic drug is a statin.
- 6. The method according to claim 1, wherein said antidyslipidemic drug is selected from the group consisting of atorvastatin, lovastatin, fluvastatin, simvastatin, pravastatin, rivastatin, itavastatin and ZD-4522.
- 7. The method according to claim 1, wherein said antidyslipidemic drug is a squalene synthase inhibitor.
- 8. The method according to claim 7, wherein said squalene synthase inhibitor is selected from the group consisting of YM-53601 and ER-27856.
- 9. The method according to claim 1, wherein said antidyslipidemic drug is a bile acid binding resin.
- 10. The method according to claim 9, wherein said bile acid binding resin is selected from the group consisting of cholestyramine and cholestipol.
- 11. The method according to claim 1, wherein said antidyslipidemic drug is an interscapular brown adipose tissue (IBAT) inhibitor.
- 12. The method according to claim 11, wherein said IBAT inhibitor is S-8921.
- 13. A method according to claim 1, wherein said GLP-1 compound is administered in a regimen which additionally comprises administration of said antidyslipidemic drug.
- 14. A method according to claim 1, wherein said GLP-1 compound and said antidyslipidemic drug are co-administered.
- 15. A method according to claim 1, wherein said GLP-1 compound is a parenteral medicament.
- 16. A method according to claim 1, wherein said antidyslipidemic drug is an oral medicament.
- 17. A method according to claim 1, wherein said GLP-1 compound and said antidyslipidemic drug are administrered in suboptimal dosages.
- 18. A method according to claim 1, wherein the effective amount of said GLP-1 compound is a dosage of from 0.5 μg/kg/day to 10 μg/kg/day.
- 19. A method according to claim 1, wherein the effective amount of said GLP-1 compound is a dosage of from 0.1 μg/kg/day to 1 μg/kg/day.
- 20. A method according to claim 1, wherein the effective amount of said antidyslipidemic drug is a dosage of from 0.01 mg/day to 10 mg/day.
- 21. Use of a GLP-1 compound and another antidyslipidemic drug for the preparation of one or more medicaments for the treatment of dyslipidemia in a patient in need thereof.
- 22. Use according to claim 21, wherein said GLP-1 compound is a stable derivative of a GLP-1 analog.
- 23. Use according to any one of claims 21-22, wherein said GLP-1 compound is Arg34, Lys26(Nε-(γ-Glu(Nα-hexadecanoyl)))-GLP-1 (7-37).
- 24. Use according to claim 21, wherein the GLP-1 compound is exendin-4 or an analog or derivative thereof.
- 25. Use according to any one of claims 21-24, wherein said antidyslipidemic drug is a statin.
- 26. Use according to any one of claims 21-25, wherein said antidyslipidemic drug is selected from the group consisting of atorvastatin, lovastatin, fluvastatin, simvastatin, pravastatin, rivastatin, itavastatin and ZD-4522.
- 27. Use according to any one of claims 21-24, wherein said antidyslipidemic drug is a squalene synthase inhibitor.
- 28. Use according to claim 27, wherein said squalene synthase inhibitor is selected from the group consisting of YM-53601 and ER-27856.
- 29. Use according to any one of claims 21-24, wherein said antidyslipidemic drug is a bile acid binding resin.
- 30. Use according to claim 29, wherein said bile acid binding resin is selected from the group consisting of cholestyramine and cholestipol.
- 31. Use according to any one of claims 21-24, wherein said antidyslipidemic drug is an IBAT inhibitor.
- 32. Use according to claim 31, wherein said IBAT inhibitor is S-8921.
- 33. Use according to any one of claims 21-32, wherein said GLP-1 compound is administered in a regimen which additionally comprises administration of said antidyslipidemic drug.
- 34. Use according to any one of claims 21-32, wherein said GLP-1 compound and said antidyslipidemic drug are co-administered.
- 35. Use according to any one of claims 21-34, wherein said GLP-1 compound is a parenteral medicament.
- 36. Use according to any one of claims 21-35, wherein said antidyslipidemic drug is an oral medicament.
- 37. Use according to any one of claims 21-36, wherein said GLP-1 compound and said antidyslipidemic drug are administrered in suboptimal dosages.
- 38. Use according to any one of claims 21-37, wherein the dosage of said GLP-1 compound is from 0.5 μg/kg/day to 10 μg/kg/day.
- 39. Use according to any one of claims 21-37, wherein the dosage of said GLP-1 compound is from 0.1 μg/kg/day to 1 μg/kg/day.
- 40. Use according to any one of claims 21-39, wherein the dosage of said antidyslipidemic drug is from 0.01 mg/day to 10 mg/day, preferably from 0.1 mg/day to 3 mg/day, most preferable less than 2 mg/day.
- 41. A method according to claim 1, wherein the effective amount of said antidyslipidemic drug is a dosage of from 0.1 mg/day to 3 mg/day.
- 42. A method according to claim 1, wherein the effective amount of said antidyslipidemic drug is a dosage of less than 2 mg/day.
Priority Claims (2)
Number |
Date |
Country |
Kind |
PA 2001 01970 |
Dec 2001 |
DK |
|
PA 2002 00759 |
May 2002 |
DK |
|
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims the benefit under 35 U.S.C. 119 of Danish applications PA 2001 01970 and PA 2002 00759 filed Dec. 29, 2001 and May 17, 2002 respectively, and of U.S. provisional application No. 60/350,088, filed Jan. 17, 2002, the contents of which are hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60350088 |
Jan 2002 |
US |